![](/img/cover-not-exists.png)
P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial
Wolinsky, J.S., Hartung, H.P., Brochet, B., Montalban, X., Naismith, R.T., Manfrini, M., Garas, M., Model, F., Hubeaux, S., Kappos, L., Hauser, S.L.Volume:
130
Language:
english
Journal:
Clinical Neurophysiology
DOI:
10.1016/j.clinph.2019.04.704
Date:
August, 2019
File:
PDF, 47 KB
english, 2019